nach oben

Wiener Medizinische Wochenschrift

Erschienen in:

20.06.2022 | Review

Association between sex and Huntington’s disease: an updated review on symptomatology and prognosis of neurodegenerative disorders

verfasst von: Nimra Hasnain, Taha Bin Arif, MBBS, Roha Shafaut, Faiza Zakaria, Syeda Zainab Fatima, Ibtehaj Ul Haque

Erschienen in: Wiener Medizinische Wochenschrift | Ausgabe 5-6/2024

Einloggen, um Zugang zu erhalten

Summary

Huntington’s disease is a rare autosomal dominant disorder presenting with chorea, rigidity, hypo-/akinesia, cognitive decline, and psychiatric disturbances. Numerous risk factors have been defined in the onset of this disease. However, the number of CAG repeats in the genes are the most crucial factor rendering patients susceptible to the disease. Studies have shown significant differences in onset and disease presentation among the sexes, which prompts analysis of the impact of different sexes on disease etiology and progression. This article therefore discusses the evidence-based role of sex in aspects of symptomatology, pathogenesis, biomarkers, progression, and prognosis of Huntington’s disease, with a secondary review of sex-linked differences in Alzheimer’s and Parkinson’s disease.

Nächster Artikel Olfactory identification, cognition, depressive symptoms, and 5-year mortality in patients with subjective cognitive decline, mild cognitive impairment, and Alzheimer’s disease

Ajitkumar A, De Jesus O. Huntington disease. Treasure Island (FL): StatPearls; 2021.

Roos RA. Huntington’s disease: a clinical review. Orphanet J Rare Dis. 2010;5:40.PubMedPubMedCentral

Walker FO. Huntington’s disease. Semin Neurol. 2007;27(2):143–50.PubMed

No authors listed. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes. The Huntington’s disease collaborative research group. Cell. 1993;72(6):971–83.

Quarrell O, O’Donovan KL, Bandmann O, Strong M. The prevalence of juvenile Huntington’s disease: a review of the literature and meta-analysis. PLoS Curr. 2012;4:e4f8606b742ef3.PubMedPubMedCentral

Zühlke C, Riess O, Schröder K, Siedlaczck I, Epplen JT, Engel W, et al. Expansion of the (CAG)n repeat causing Huntington’s disease in 352 patients of German origin. Hum Mol Genet. 1993;2(9):1467–9.PubMed

Foroud T, Gray J, Ivashina J, Conneally PM. Differences in duration of Huntington’s disease based on age at onset. J Neurol Neurosurg Psychiatry. 1999;66(1):52–6.PubMedPubMedCentral

Telenius H, Kremer HP, Theilmann J, Andrew SE, Almqvist E, Anvret M, et al. Molecular analysis of juvenile Huntington disease: the major influence on (CAG)n repeat length is the sex of the affected parent. Hum Mol Genet. 1993;2(10):1535–40.PubMed

Trottier Y, Biancalana V, Mandel JL. Instability of CAG repeats in Huntington’s disease: relation to parental transmission and age of onset. J Med Genet. 1994;31(5):377–82.PubMedPubMedCentral

10.

Nørremølle A, Sørensen SA, Fenger K, Hasholt L. Correlation between magnitude of CAG repeat length alterations and length of the paternal repeat in paternally inherited Huntington’s disease. Clin Genet. 1995;47(3):113–7.PubMed

11.

Kehoe P, Krawczak M, Harper PS, Owen MJ, Jones AL. Age of onset in Huntington disease: sex specific influence of apolipoprotein E genotype and normal CAG repeat length. J Med Genet. 1999;36(2):108–11.PubMedPubMedCentral

12.

Wheeler VC, Persichetti F, McNeil SM, Mysore JS, Mysore SS, MacDonald ME, et al. Factors associated with HD CAG repeat instability in Huntington disease. J Med Genet. 2007;44(11):695–701.PubMedPubMedCentral

13.

Strittmatter WJ, Saunders AM, Schmechel D, Pericak-Vance M, Enghild J, Salvesen GS, et al. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci U S A. 1993;90(5):1977–81.PubMedPubMedCentral

14.

Miyata M, Smith JD. Apolipoprotein E allele-specific antioxidant activity and effects on cytotoxicity by oxidative insults and beta-amyloid peptides. Nat Genet. 1996;14(1):55–61.PubMed

15.

Nicoll JA, Roberts GW, Graham DI. Apolipoprotein E epsilon 4 allele is associated with deposition of amyloid beta-protein following head injury. Nat Med. 1995;1(2):135–7.PubMed

16.

Novak MJ, Tabrizi SJ. Huntington’s disease. BMJ. 2010;340:c3109.PubMed

17.

Zielonka D, Marinus J, Roos RA, De Michele G, Di Donato S, Putter H, et al. The influence of gender on phenotype and disease progression in patients with Huntington’s disease. Parkinsonism Relat Disord. 2013;19(2):192–7.PubMed

18.

Zielonka D, Ren M, De Michele G, Roos RAC, Squitieri F, Bentivoglio AR, et al. The contribution of gender differences in motor, behavioral and cognitive features to functional capacity, independence and quality of life in patients with Huntington’s disease. Parkinsonism Relat Disord. 2018;49:42–7.PubMed

19.

Paulsen JS. Cognitive impairment in Huntington disease: diagnosis and treatment. Curr Neurol Neurosci Rep. 2011;11(5):474–83.PubMedPubMedCentral

20.

Solomon AC, Stout JC, Johnson SA, Langbehn DR, Aylward EH, Brandt J, et al. Verbal episodic memory declines prior to diagnosis in Huntington’s disease. Neuropsychologia. 2007;45(8):1767–76.PubMedPubMedCentral

21.

Filoteo JV, Delis DC, Roman MJ, Demadura T, Ford E, Butters N, et al. Visual attention and perception in patients with Huntington’s disease: comparisons with other subcortical and cortical dementias. J Clin Exp Neuropsychol. 1995;17(5):654–67.PubMed

22.

Marder K, Zhao H, Myers RH, Cudkowicz M, Kayson E, Kieburtz K, et al. Rate of functional decline in Huntington’s disease. Huntington study group. Neurology. 2000;54(2):452–8.PubMed

23.

Saleh N, Moutereau S, Azulay JP, Verny C, Simonin C, Tranchant C, et al. High insulinlike growth factor I is associated with cognitive decline in Huntington disease. Neurology. 2010;75(1):57–63.PubMed

24.

López-Sendón JL, Royuela A, Trigo P, Orth M, Lange H, Reilmann R, et al. What is the impact of education on Huntington’s disease? Mov Disord. 2011;26(8):1489–95.PubMed

25.

Louis ED, Vonsattel JP. The emerging neuropathology of essential tremor. Mov Disord. 2008;23(2):174–82.PubMedPubMedCentral

26.

Hubble JP, Busenbark KL, Pahwa R, Lyons K, Koller WC. Clinical expression of essential tremor: effects of gender and age. Mov Disord. 1997;12(6):969–72.PubMed

27.

Hardesty DE, Maraganore DM, Matsumoto JY, Louis ED. Increased risk of head tremor in women with essential tremor: longitudinal data from the Rochester epidemiology project. Mov Disord. 2004;19(5):529–33.PubMed

28.

Cossu G, Colosimo C. Hyperkinetic movement disorder emergencies. Curr Neurol Neurosci Rep. 2017;17(1):6.PubMed

29.

Savitt D, Jankovic J. Tardive syndromes. J Neurol Sci. 2018;389:35–42.PubMed

30.

van Duijn E, Craufurd D, Hubers AA, Giltay EJ, Bonelli R, Rickards H, et al. Neuropsychiatric symptoms in a European Huntington’s disease cohort (REGISTRY). J Neurol Neurosurg Psychiatry. 2014;85(12):1411–8.PubMed

31.

Dale M, Maltby J, Shimozaki S, Cramp R, Rickards H. Disease stage, but not sex, predicts depression and psychological distress in Huntington’s disease: a European population study. J Psychosom Res. 2016;80:17–22.PubMed

32.

Wittchen HU, Jacobi F, Rehm J, Gustavsson A, Svensson M, Jonsson B, et al. The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur Neuropsychopharmacol. 2011;21(9):655–79.PubMed

33.

Kessler RC, McGonagle KA, Swartz M, Blazer DG, Nelson CB. Sex and depression in the national comorbidity survey. I: lifetime prevalence, chronicity and recurrence. J Affect Disord. 1993;29(2–3):85–96.PubMed

34.

Rowe KC, Paulsen JS, Langbehn DR, Wang C, Mills J, Beglinger LJ, et al. Patterns of serotonergic antidepressant usage in prodromal Huntington disease. Psychiatry Res. 2012;196(2–3):309–14.PubMedPubMedCentral

35.

Chu EM, O’Neill M, Purkayastha DD, Knight C. Huntington’s disease: a forensic risk factor in women. J Clin Mov Disord. 2019;6:3.PubMedPubMedCentral

36.

Aziz NA, van der Burg JM, Landwehrmeyer GB, Brundin P, Stijnen T, Roos RA. Weight loss in Huntington disease increases with higher CAG repeat number. Neurology. 2008;71(19):1506–13.PubMed

37.

Costa de Miranda R, Di Lorenzo N, Andreoli A, Romano L, De Santis GL, Gualtieri P, et al. Body composition and bone mineral density in Huntington’s disease. Nutrition. 2019;59:145–9.PubMed

38.

Beyer C, Pilgrim C, Reisert I. Dopamine content and metabolism in mesencephalic and diencephalic cell cultures: sex differences and effects of sex steroids. J Neurosci. 1991;11(5):1325–33.PubMedPubMedCentral

39.

Laakso A, Vilkman H, Bergman J, Haaparanta M, Solin O, Syvalahti E, et al. Sex differences in striatal presynaptic dopamine synthesis capacity in healthy subjects. Biol Psychiatry. 2002;52(7):759–63.PubMed

40.

Wong KK, Muller ML, Kuwabara H, Studenski SA, Bohnen NI. Gender differences in nigrostriatal dopaminergic innervation are present at young-to-middle but not at older age in normal adults. J Clin Neurosci. 2012;19(1):183–4.PubMed

41.

Jankovic J, Hallett M, Okun MS, Comella CL, Fahn S. Principles and practice of movement disorders E‑book. Elsevier; 2021.

42.

Kara M, Smith ND. Sex differences in Parkinson’s disease and other movement disorders. Exp Neurol. 2014;259:44–56.

43.

Tsang KL, Ho SL, Lo SK. Estrogen improves motor disability in parkinsonian postmenopausal women with motor fluctuations. Neurology. 2000;54(12):2292–8.PubMed

44.

Weaver CE Jr., Park-Chung M, Gibbs TT, Farb DH. 17beta-estradiol protects against NMDA-induced excitotoxicity by direct inhibition of NMDA receptors. Brain Res. 1997;761(2):338–41.PubMed

45.

Hogervorst E, Williams J, Budge M, Barnetson L, Combrinck M, Smith AD. Serum total testosterone is lower in men with Alzheimer’s disease. Neuro Endocrinol Lett. 2001;22(3):163–8.PubMed

46.

Okun MS, McDonald WM, DeLong MR. Refractory nonmotor symptoms in male patients with Parkinson disease due to testosterone deficiency: a common unrecognized comorbidity. Arch Neurol. 2002;59(5):807–11.PubMed

47.

Militello A, Vitello G, Lunetta C, Toscano A, Maiorana G, Piccoli T, et al. The serum level of free testosterone is reduced in amyotrophic lateral sclerosis. J Neurol Sci. 2002;195(1):67–70.PubMed

48.

Markianos M, Panas M, Kalfakis N, Vassilopoulos D. Plasma testosterone, dehydroepiandrosterone sulfate, and cortisol in female patients with Huntington’s disease. Neuro Endocrinol Lett. 2007;28(2):199–203.PubMed

49.

Saleh N, Moutereau S, Durr A, Krystkowiak P, Azulay JP, Tranchant C, et al. Neuroendocrine disturbances in Huntington’s disease. PLoS One. 2009;4(3):e4962.PubMedPubMedCentral

50.

De Pablo-Fernández E, Lees AJ, Holton JL, Warner TT. Prognosis and neuropathologic correlation of clinical subtypes of parkinson disease. JAMA Neurol. 2019;76(4):470–9.PubMedPubMedCentral

51.

Haaxma CA, Bloem BR, Borm GF, Oyen WJ, Leenders KL, Eshuis S, et al. Gender differences in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2007;78(8):819–24.PubMed

52.

Benedetti MD, Maraganore DM, Bower JH, McDonnell SK, Peterson BJ, Ahlskog JE, et al. Hysterectomy, menopause, and estrogen use preceding Parkinson’s disease: an exploratory case-control study. Mov Disord. 2001;16(5):830–7.PubMed

53.

Latourelle JC, Beste MT, Hadzi TC, Miller RE, Oppenheim JN, Valko MP, et al. Large-scale identification of clinical and genetic predictors of motor progression in patients with newly diagnosed Parkinson’s disease: a longitudinal cohort study and validation. Lancet Neurol. 2017;16(11):908–16.PubMedPubMedCentral

54.

Melcangi RC, Giatti S, Garcia-Segura LM. Levels and actions of neuroactive steroids in the nervous system under physiological and pathological conditions: sex-specific features. Neurosci Biobehav Rev. 2016;67:25–40.PubMed

55.

Lavalaye J, Booij J, Reneman L, Habraken JB, van Royen EA. Effect of age and gender on dopamine transporter imaging with [123I]FP-CIT SPET in healthy volunteers. Eur J Nucl Med. 2000;27(7):867–9.PubMed

56.

Meoni S, Macerollo A, Moro E. Sex differences in movement disorders. Nat Rev Neurol. 2020;16(2):84–96.PubMed

57.

Arning L, Saft C, Wieczorek S, Andrich J, Kraus PH, Epplen JT. NR2A and NR2B receptor gene variations modify age at onset in Huntington disease in a sex-specific manner. Hum Genet. 2007;122(2):175–82.PubMed

58.

Gan-Or Z, Bar-Shira A, Mirelman A, Gurevich T, Kedmi M, Giladi N, et al. LRRK2 and GBA mutations differentially affect the initial presentation of Parkinson disease. Neurogenetics. 2010;11(1):121–5.PubMed

59.

Szewczyk-Krolikowski K, Tomlinson P, Nithi K, Wade-Martins R, Talbot K, Ben-Shlomo Y, et al. The influence of age and gender on motor and non-motor features of early Parkinson’s disease: initial findings from the Oxford Parkinson disease center (OPDC) discovery cohort. Parkinsonism Relat Disord. 2014;20(1):99–105.PubMed

60.

Cholerton B, Johnson CO, Fish B, Quinn JF, Chung KA, Peterson-Hiller AL, et al. Sex differences in progression to mild cognitive impairment and dementia in Parkinson’s disease. Parkinsonism Relat Disord. 2018;50:29–36.PubMedPubMedCentral

61.

Zielonka D, Stawinska-Witoszynska B. Gender differences in non-sex linked disorders: insights from Huntington’s disease. Front Neurol. 2020;11:571.PubMedPubMedCentral

62.

Beinhoff U, Tumani H, Brettschneider J, Bittner D, Riepe MW. Gender-specificities in Alzheimer’s disease and mild cognitive impairment. J Neurol. 2008;255(1):117–22.PubMed

63.

Howlett DR, Richardson JC, Austin A, Parsons AA, Bate ST, Davies DC, et al. Cognitive correlates of Abeta deposition in male and female mice bearing amyloid precursor protein and presenilin‑1 mutant transgenes. Brain Res. 2004;1017(1–2):130–6.PubMed

64.

Barnes LL, Wilson RS, Bienias JL, Schneider JA, Evans DA, Bennett DA. Sex differences in the clinical manifestations of Alzheimer disease pathology. Arch Gen Psychiatry. 2005;62(6):685–91.PubMed

65.

Seshadri S, Wolf PA, Beiser A, Au R, McNulty K, White R, et al. Lifetime risk of dementia and Alzheimer’s disease. The impact of mortality on risk estimates in the Framingham study. Neurology. 1997;49(6):1498–504.PubMed

66.

Andersen K, Launer LJ, Dewey ME, Letenneur L, Ott A, Copeland JR, et al. Gender differences in the incidence of AD and vascular dementia: the EURODEM studies. EURODEM incidence research group. Neurology. 1999;53(9):1992–7.PubMed

67.

Chene G, Beiser A, Au R, Preis SR, Wolf PA, Dufouil C, et al. Gender and incidence of dementia in the Framingham heart study from mid-adult life. Alzheimers Dement. 2015;11(3):310–20.PubMed

68.

Hanamsagar R, Bilbo SD. Sex differences in neurodevelopmental and neurodegenerative disorders: focus on microglial function and neuroinflammation during development. J Steroid Biochem Mol Biol. 2016;160:127–33.PubMed

69.

Hall JR, Wiechmann AR, Johnson LA, Edwards M, Barber RC, Winter AS, et al. Biomarkers of vascular risk, systemic inflammation, and microvascular pathology and neuropsychiatric symptoms in Alzheimer’s disease. J Alzheimers Dis. 2013;35(2):363–71.PubMedPubMedCentral

70.

Mastrokolias A, Ariyurek Y, Goeman JJ, van Duijn E, Roos RA, van der Mast RC, et al. Huntington’s disease biomarker progression profile identified by transcriptome sequencing in peripheral blood. Eur J Hum Genet. 2015;23(10):1349–56.PubMedPubMedCentral

71.

Corey-Bloom J, Haque A, Aboufadel S, Snell C, Fischer RS, Granger SW, et al. Uric acid as a potential peripheral biomarker for disease features in Huntington’s patients. Front Neurosci. 2020;14:73.PubMedPubMedCentral

72.

Gutierrez A, Corey-Bloom J, Thomas EA, Desplats P. Evaluation of biochemical and epigenetic measures of peripheral brain-derived neurotrophic factor (BDNF) as a biomarker in Huntington’s disease patients. Front Mol Neurosci. 2020;12:335.PubMedPubMedCentral

73.

Lommatzsch M, Zingler D, Schuhbaeck K, Schloetcke K, Zingler C, Schuff-Werner P, et al. The impact of age, weight and gender on BDNF levels in human platelets and plasma. Neurobiol Aging. 2005;26(1):115–23.PubMed

74.

Chang KH, Wu YR, Chen YC, Chen CM. Plasma inflammatory biomarkers for Huntington’s disease patients and mouse model. Brain Behav Immun. 2015;44:121–7.PubMed

75.

Pekmezovic T, Svetel M, Maric J, Dujmovic-Basuroski I, Dragasevic N, Keckarevic M, et al. Survival of Huntington’s disease patients in Serbia: longer survival in female patients. Eur J Epidemiol. 2007;22(8):523–6.PubMed

76.

Byars JA, Beglinger LJ, Moser DJ, Gonzalez-Alegre P, Nopoulos P. Substance abuse may be a risk factor for earlier onset of Huntington disease. J Neurol. 2012;259(9):1824–31.PubMed

77.

Myers RH, Sax DS, Koroshetz WJ, Mastromauro C, Cupples LA, Kiely DK, et al. Factors associated with slow progression in Huntington’s disease. Arch Neurol. 1991;48(8):800–4.PubMed

78.

Cao JK, Detloff PJ, Gardner RG, Stella N. Sex-dependent behavioral impairments in the HdhQ350/+ mouse line. Behav Brain Res. 2018;337:34–45.PubMed

79.

Pietropaolo S, Delage P, Cayzac S, Crusio WE, Cho YH. Sex-dependent changes in social behaviors in motor pre-symptomatic R6/1 mice. PLoS One. 2011;6(5):e19965.PubMedPubMedCentral

80.

Kuljis DA, Gad L, Loh DH, MacDowell Kaswan Z, Hitchcock ON, Ghiani CA, et al. Sex differences in circadian dysfunction in the BACHD mouse model of Huntington’s disease. PLoS One. 2016;11(2):e147583.PubMedPubMedCentral

81.

Corrochano S, Renna M, Osborne G, Carter S, Stewart M, May J, et al. Reducing Igf-1r levels leads to paradoxical and sexually dimorphic effects in HD mice. PLoS One. 2014;9(8):e105595.PubMedPubMedCentral

82.

Pfalzer AC, Wages PA, Porter NA, Bowman AB. Striatal cholesterol precursors are altered with age in female Huntington’s disease model mice. J Huntingtons Dis. 2019;8(2):161–9.PubMedPubMedCentral

83.

Mo C, Pang TY, Ransome MI, Hill RA, Renoir T, Hannan AJ. High stress hormone levels accelerate the onset of memory deficits in male Huntington’s disease mice. Neurobiol Dis. 2014;69:248–62.PubMed

84.

Mo C, Renoir T, Pang TY, Hannan AJ. Short-term memory acquisition in female Huntington’s disease mice is vulnerable to acute stress. Behav Brain Res. 2013;253:318–22.PubMed

85.

Polyzos AA, Wood NI, Williams P, Wipf P, Morton AJ, McMurray CT. XJB-5-131-mediated improvement in physiology and behaviour of the R6/2 mouse model of Huntington’s disease is age- and sex- dependent. PLoS ONE. 2018;13(4):e194580.PubMedPubMedCentral

86.

Skillings EA, Morton AJ. Delayed onset and reduced cognitive deficits through pre-conditioning with 3‑nitropropionic acid is dependent on sex and CAG repeat length in the R6/2 mouse model of Huntington’s disease. J Huntingtons Dis. 2016;5(1):19–32.PubMed

87.

Khodagholi F, Maleki A, Motamedi F, Mousavi MA, Rafiei S, Moslemi M. Oxytocin prevents the development of 3‑NP-induced anxiety and depression in male and female rats: possible interaction of OXTR and mGluR2. Cell Mol Neurobiol. 2022;42(4):1105–23. https://doi.org/10.1007/s10571-020-01003-0.CrossRefPubMed

88.

Connor B, Sun Y, von Hieber D, Tang SK, Jones KS, Maucksch C. AAV1/2-mediated BDNF gene therapy in a transgenic rat model of Huntington’s disease. Gene Ther. 2016;23(3):283–95.PubMed

Titel: Association between sex and Huntington’s disease: an updated review on symptomatology and prognosis of neurodegenerative disorders
verfasst von: Nimra Hasnain
Taha Bin Arif, MBBS
Roha Shafaut
Faiza Zakaria
Syeda Zainab Fatima
Ibtehaj Ul Haque
Publikationsdatum: 20.06.2022
Verlag: Springer Vienna
Erschienen in: Wiener Medizinische Wochenschrift / Ausgabe 5-6/2024
Print ISSN: 0043-5341
Elektronische ISSN: 1563-258X
DOI: https://doi.org/10.1007/s10354-022-00941-2

Springer Medizin Österreich

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5-6/2024

Scale for the assessment and rating of ataxia (SARA): Übersetzung und kulturelle Anpassung an den deutschsprachigen Raum

Epidemiology, microbiology, and outcomes of infective endocarditis in a tertiary center in Jordan

Hemispherotomy in an infant with hemimegalencephaly and Ohtahara syndrome

Olfactory identification, cognition, depressive symptoms, and 5-year mortality in patients with subjective cognitive decline, mild cognitive impairment, and Alzheimer’s disease

Acute bilateral vision loss after endovascular treatment of an intracranial aneurysm